Indication

Paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells primarily affecting the hematologic and vascular systems in adults. Read more about Paroxysmal nocturnal hemoglobinuria

9 drugs 7 manufacturers

Advertisement

Drugs that treat it

Common Paroxysmal nocturnal hemoglobinuria therapies.

Showing 1–9 of 9 drugs

Filter & compare in the drug finder →Opens the drug finder with Paroxysmal nocturnal hemoglobinuria preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Paroxysmal nocturnal hemoglobinuria.

Paroxysmal nocturnal hemoglobinuria is a rare, acquired clonal disorder of hematopoietic stem cells primarily affecting the hematologic and vascular systems in adults.

It is caused by somatic mutations in the X-linked *PIGA* gene, which leads to a deficiency of glycosylphosphatidylinositol (GPI) anchors and the subsequent loss of surface complement regulatory proteins, notably CD55 and CD59.

This absence leaves erythrocytes vulnerable to unchecked complement-mediated destruction, driving chronic intravascular hemolysis.

Clinically, the disease is characterized by a classic triad of hemolytic anemia, an elevated propensity for venous and arterial thrombosis, and varying degrees of bone marrow failure, often presenting with hemoglobinuria, fatigue, and organ damage.

Personalize your experience

Follow Paroxysmal nocturnal hemoglobinuria and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it